Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
58 hedge funds and large institutions have $14.2M invested in Nymox Pharmaceutical Corp in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
1% more capital invested
Capital invested by funds: $14M → $14.2M (+$193K)
9% less funds holding
Funds holding: 64 → 58 (-6)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
68% less call options, than puts
Call options by funds: $27K | Put options by funds: $84K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$241K |
| 2 |
JP Morgan Chase
New York
|
+$192K |
| 3 |
Renaissance Technologies
New York
|
+$70K |
| 4 |
Morgan Stanley
New York
|
+$61K |
| 5 |
Invesco
Atlanta,
Georgia
|
+$60.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$250K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$150K |
| 3 |
Jane Street
New York
|
-$106K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$104K |
| 5 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
-$73K |
NYMX Hedge Fund Activity: Q4 2020 in Review
58 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2020, worth a combined $14.2M — up 1.4% from $14M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NYMX and 4 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 21 added.
The largest buyer was State Street, adding an estimated $241K. The largest seller was Worth Venture Partners, exiting entirely with an estimated $250K sold.
- 58 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2020, down from 64 in Q3 2020.
- Funds reported $14.2M of Nymox Pharmaceutical Corp stock for Q4 2020, up 1.4% quarter-over-quarter.
- 4 funds opened new Nymox Pharmaceutical Corp positions in Q4 2020 and 10 closed out, a net change of -6 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q4 2020 was State Street, an estimated $241K added.
- The largest Nymox Pharmaceutical Corp seller in Q4 2020 was Worth Venture Partners, an estimated $250K sold.
Based on aggregated 13F filings for Q4 2020.